Artefenomel对间日疟无性体及传播期配子体的抗疟活性:实验性血液阶段感染研究
该研究在8名健康疟疾初治志愿者中静脉接种间日疟血液阶段虫体后,单次口服200 mg artefenomel。所有受试者均出现初始虫体清除,但7人在11–14天后复发;配子体血症均出现并在给药后4–8天清除,配子体血症高峰时75%受试者具蚊媒传播性。
要点
- 单次200 mg artefenomel可致间日疟初始虫体清除,但7/8受试者复发。
- 间日疟配子体血症在给药后4–8天清除,高峰时75%受试者具传播性。
- 估计最低抑虫浓度0.62 ng/mL,90%最大效应最低杀虫浓度0.83 ng/mL。
核心结论
- Artefenomel在间日疟血液阶段感染中显示体内抗疟活性,支持其作为间日疟治疗候选药物的进一步临床开发。
研究设计与样本
- 研究为间日疟志愿者感染研究,纳入8名健康、疟疾初治受试者,静脉接种血液阶段间日疟原虫后单次口服200 mg artefenomel。
主要发现
- 所有受试者在artefenomel给药后均出现初始虫体清除,48小时log10虫体减少比为1.67,虫体清除半衰期为8.67小时。
- 7名受试者在给药后11–14天出现复发。
- 估计最低抑虫浓度为0.62 ng/mL,达到90%最大效应的最低杀虫浓度为0.83 ng/mL。
- 预测单次300 mg剂量以95%确定性清除每毫升10^9个虫体。
- 所有受试者均出现配子体血症,给药后4–8天清除;配子体血症高峰时75%受试者对蚊媒具感染性。
关键数值与推荐
- 单次口服artefenomel 200 mg后48小时log10虫体减少比为1.67,虫体清除半衰期为8.67小时。
- 最低抑虫浓度为0.62 ng/mL,达到90%最大效应的最低杀虫浓度为0.83 ng/mL。
- 预测单次300 mg剂量以95%确定性清除每毫升10^9个虫体。
临床怎么用
- Artefenomel单次200 mg可清除间日疟初始虫体,但复发常见,需关注其与抗复发药物的联合策略。
- 配子体血症在给药后4–8天清除,提示其可能影响传播期,但需进一步验证。
局限性
- 研究样本量小(8名健康志愿者),且为实验性血液阶段感染,结果外推至自然感染人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interventions that effectively target Plasmodium vivax are critical for the future control and elimination of malaria. We conducted a P. vivax volunteer infection study to characterize the antimalarial activity of artefenomel, a new drug candidate. METHODS: Eight healthy, malaria-naive participants were intravenously inoculated with blood-stage P. vivax and subsequently received a single oral 200-mg dose of artefenomel. Blood samples were collected to monitor the development and clearance of parasitemia, and plasma artefenomel concentration. Mosquito feeding assays were conducted before artefenomel dosing to investigate parasite transmissibility. RESULTS: Initial parasite clearance occurred in all participants after artefenomel administration (log10 parasite reduction ratio over 48 hours, 1.67; parasite clearance half-life, 8.67 hours). Recrudescence occurred in 7 participants 11-14 days after dosing. A minimum inhibitory concentration of 0.62 ng/mL and minimum parasiticidal concentration that achieves 90% of maximum effect of 0.83 ng/mL were estimated, and a single 300-mg dose was predicted to clear 109 parasites per milliliter with 95% certainty. Gametocytemia developed in all participants and was cleared 4-8 days after dosing. At peak gametocytemia, 75% of participants were infectious to mosquitoes. CONCLUSIONS: The in vivo antimalarial activity of artefenomel supports its further clinical development as a treatment for P. vivax malaria. CLINICAL TRIALS REGISTRATION: NCT02573857.
引用
- Collins KA, Abd-Rahman AN, Marquart L, et al. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection. J Infect Dis. 2022. PMID: 32479608. doi:10.1093/infdis/jiaa287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。